Archvest Wealth Advisors Buys Amgen Stake Following Guidance Hike

Key Facts

In a move reflecting growing confidence in the biotechnology sector, institutional investors are strengthening their positions in major American pharmaceutical firms. According to reports, Archvest Wealth Advisors Inc. acquired a new stake in Amgen Inc., purchasing 3,801 shares valued at approximately $1.19 million during the fourth quarter. This acquisition follows Amgen's recent quarterly earnings beat and a subsequent upward revision of its full-year 2026 financial guidance.

This institutional activity occurs amid a mixed performance for the healthcare sector, as Amgen seeks to solidify its market position against peers like Gilead Sciences and Biogen. Per market data, investors are closely monitoring profit margins after U.S. GDP growth data released on May 28, 2026, showed a 1.6% expansion—missing the 2% forecast—which often increases the appeal of defensive stocks with stable earnings.

AMGN shares remain in focus following the close on June 3, 2026, as traders assess the sustainability of the bullish momentum triggered by the guidance hike. Investors should watch upcoming U.S. inflation data, specifically the Personal Consumption Expenditures (PCE) updates, to gauge how financing costs might impact the company's research and development expansion plans.